-2%
Hepanib (Sorafenib):
- Hepatocellular Carcinoma (HCC): For patients with unresectable HCC.
- Renal Cell Carcinoma (RCC): For patients with advanced RCC.
Sorafenib inhibits tumor cell proliferation by targeting multiple kinases, including RAF kinases (CRAF, BRAF), receptor tyrosine kinases (VEGFR-1, VEGFR-2, VEGFR-3, PDGFR-β), and others involved in angiogenesis and tumor growth.
